Clinical Scorecard: Approaches to Treating Liver Metastases Arising from Uveal Melanoma
At a Glance
Category
Detail
Condition
Uveal melanoma with liver metastases
Key Mechanisms
Mutually exclusive mutations in GNAQ or GNA11 activating MAPK, PI3K, AKT, YAP1 pathways; chromosomal aberrations including monosomy 3 and BAP1 mutations leading to aggressive tumor behavior and metastasis
Target Population
Adults diagnosed with uveal melanoma, particularly those with metastatic or unresectable disease and HLA-A*02:01 genotype
Care Setting
Specialized oncology and ophthalmology centers with access to systemic and liver-directed therapies
Key Highlights
Uveal melanoma is the most common primary intraocular malignancy in adults with distinct genetic and clinical features from cutaneous melanoma.
Liver metastases occur in approximately 90% of metastatic uveal melanoma cases, with median overall survival around 1 year after detection.
Tebentafusp is the first systemic treatment to demonstrate improved overall survival in metastatic uveal melanoma patients with HLA-A*02:01 genotype.
Guideline-Based Recommendations
Diagnosis
Diagnosis primarily via fundoscopy and imaging modalities such as ultrasonography and optical coherence tomography.
Biopsy is mainly reserved for prognostic purposes.
Surveillance intensity stratified by metastatic risk: annual imaging for low-risk, hepatic imaging every 3–6 months for high-risk patients.
Management
Primary tumor treatment includes plaque brachytherapy (ruthenium-106 or iodine-125) and proton beam radiotherapy for local control.
Systemic treatment options historically show limited efficacy; tebentafusp approved for metastatic/unresectable disease with HLA-A*02:01 genotype.
Liver-directed therapies include surgical resection, radioembolization, chemoembolization, immune-embolization, isolated hepatic perfusion, and percutaneous hepatic perfusion.
Adjuvant systemic therapy is not routinely recommended in non-metastatic disease outside clinical trials.
Monitoring & Follow-up
Enhanced surveillance may detect earlier hepatic lesions but has not yet improved overall survival.
Long-term hepatic imaging recommended for at least 10 years in high-risk patients.
Risks
High metastatic risk associated with monosomy 3, BAP1 mutations, and chromosome 8q gain.
Metastatic disease carries poor prognosis with median overall survival approximately 1 year after liver metastasis detection.
Patient & Prescribing Data
Patients with metastatic or unresectable uveal melanoma expressing HLA-A*02:01 genotype
Tebentafusp is the only systemic therapy shown to improve overall survival; other systemic therapies have limited efficacy. Liver-directed therapies are important adjuncts.
Clinical Best Practices
Use plaque brachytherapy or proton beam radiotherapy for local tumor control in primary uveal melanoma.
Perform risk stratification for metastatic surveillance to guide imaging frequency.
Consider tebentafusp for eligible patients with metastatic disease and HLA-A*02:01 genotype.
Employ liver-directed therapies as part of multidisciplinary management for liver metastases.
Monitor patients long-term with hepatic imaging due to late metastatic risk.
